Start at the source.
Work with established Ghana-based relationships to build a traceable supply of Voacanga africana root bark.
Sourcing relationships
Pharmaceutical-grade alkaloids, from the source.
Ethovoa Sciences is a development-stage pharmaceutical company working toward GMP-qualified supply of ibogaine hydrochloride and its registered starting material, voacangine.
B2B. We supply licensed manufacturers and research institutions only.
Our approach
Ethovoa is developing an integrated model that connects botanical sourcing and upstream processing in Ghana with specialist pharmaceutical development partners. We are building toward a qualified, reproducible supply of voacangine and downstream APIs.
Work with established Ghana-based relationships to build a traceable supply of Voacanga africana root bark.
Sourcing relationships
Develop a consistent voacangine intermediate, with characterisation and quality requirements agreed with our development partners.
Upstream development
Engage a qualified Contract Development and Manufacturing Organization to establish the pathway to GMP-grade ibogaine hydrochloride.
Partner discussions
Origin / Ghana, West Africa
We treat the source material as a long-term asset, not a commodity. Our sourcing follows the Nagoya Protocol's access and benefit-sharing framework, with formal engagement through Ghana's national competent authority. The genetic resource itself, not merely the finished extract, is the basis of that commitment.
Our objective is a sourcing and processing framework that supports the rigorous regulatory requirements of future pharmaceutical customers.
Organization
Our team combines pharmaceutical chemistry, GMP manufacturing experience and direct in-country relationships across Ghana's growing regions. It was built over years, not assembled for this project.
Ian MacKenna
Founder, Chief Executive Officer and Lead Chemist
Ian holds a chemistry background from the University of New Orleans and has worked specifically in ibogaine chemistry for approximately three years. He has spent four months in country in Ghana building the sourcing and processing relationships that the programme is founded on.
He is directly responsible for the synthesis pathway, the technical documentation package and engagement with development and manufacturing partners. He speaks and moderates regularly at conferences in the field.
Ian is supported by a board and operating group whose contributions span the disciplines this programme depends on. We introduce them directly in partner conversations.
Our development focus
A focused development programme today, with room to explore the broader potential of Voacanga-derived alkaloids over time.
Lead development programme
Our initial target is GMP-grade voacangine derived from Ghana-sourced botanical material. We are seeking a qualified CDMO for starting-material assessment, analytical and process development, and a defined chemical pathway toward ibogaine hydrochloride.
Current stage: development and partner evaluation. No commercial GMP supply is being offered at this stage.
Development goals are not statements of regulatory approval or GMP certification. Product specifications, manufacturing scope and availability will be established through the appropriate development and qualification work. Read the full development notice.
Let's start a conversation
Have the capabilities, perspective or research needs to help shape this programme? We supply licensed manufacturers and research institutions.
Please do not include confidential technical information or patient data in an initial inquiry.